טוען...
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
LE Dockery, CC Gunderson, KN Moore Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, an...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2017-06-01
|
| סדרה: | OncoTargets and Therapy |
| נושאים: | |
| גישה מקוונת: | https://www.dovepress.com/rucaparib-the-past-present-and-future-of-a-newly-approved-parp-inhibit-peer-reviewed-article-OTT |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|